Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus METI DERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus METI DERM.
ARAZLO vs METI-DERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
METI-DERM contains methylprednisolone aceponate, a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit pro-inflammatory cytokines, phospholipase A2, and prostaglandin synthesis, thereby reducing inflammation, pruritus, and vasodilation.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Apply a thin film topically to affected area once or twice daily.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Terminal elimination half-life: 6–8 hours in healthy adults; prolonged to 12–15 hours in severe renal impairment (CrCl <30 mL/min).
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Renal: ~60% as unchanged drug and metabolites; biliary/fecal: ~35% as metabolites and unchanged drug; minor respiratory elimination.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid